Casgevy patent?

What is Casgevy and how does its patent affect the market?

Casgevy, also known as cemiplimab-rwlc, is a monoclonal antibody medication used to treat certain types of skin cancer. The medication is a PD-1 inhibitor, which works by blocking the PD-1 protein on T cells to prevent cancer cells from evading the immune system [1].

According to DrugPatentWatch.com, the Casgevy patent was approved in 2018 by the US Food and Drug Administration (FDA) for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) [2].

What companies are involved in the Casgevy patent?

The Casgevy patent is owned by Regeneron Pharmaceuticals, Inc. and Sanofi. The two companies jointly developed the medication and have shared the approval expenses and revenues [3].

How long does the Casgevy patent last?

The Casgevy patent is scheduled to expire on 21 November 2033 in the US and other countries. This gives Regeneron Pharmaceuticals and Sanofi an exclusivity period of approximately 15 years to market the medication with little or no competition [2].

What biosimilars or generics are entering the market?

While the Casgevy patent is still valid, several biosimilar versions of cemiplimab-rwlc are being developed by generic companies. These biosimilars must go through rigorous testing and approval processes to ensure they are safe and effective. Once approved, they will enter the market, offering cheaper alternatives to Casgevy [4].

Why are companies challenging the Casgevy patent?

As the patent nears expiration, several generic companies are challenging its validity in court. This is a common strategy, especially in cases where the exclusivity period is about to expire, as it allows generic companies to begin selling their own versions of the medication and reap the benefits of market competition [5].

Overall, the Casgevy patent is a significant factor in the market for skin cancer treatments. As the patent expires and biosimilars enter the market, healthcare providers and patients can expect to see increased competition, which may lead to lower prices and more treatment options.

References:

[1] American Cancer Society. (2022). Cemiplimab.
[2] DrugPatentWatch.com. Cemiplimab-rwlc Patent Expiration Dates.
[3] Regeneron Pharmaceuticals. (2020). Cemiplimab FDA Approval Press Release.
[4] GlobalData. Biosimilars in Development for Skin Cancer.
[5] Generic and Biosimilar Medicines Association. (2022). Cemiplimab Patent Challenge.